Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (“ANDA”) for
Topiramate HCl 25, 50, 100 and 200 mg tablets from Wockhardt Limited.
Topiramate is indicated as a treatment of epilepsy and migraine. The market size of Topiramate
Tablet in the USA was ~USD 111.47 Mn (MAT December 2024)1 as per IQVIA.
The acquisition will be funded through the Initial Public Offer (“IPO”) proceeds raised by Senores Pharmaceuticals Limited.This is
in line with the Objects of the IPO stated in the Red Herring Prospectus.
Senores Pharmaceuticals Limited is a global, research-driven
pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical
products predominantly for the US, Canada, and other regulated and emerging markets across various
therapeutic areas and dosage forms.
The companies’ current portfolio includes 61 ANDA and 22 CMO/CDMO commercial products that
are permitted for distribution in the USA. Senores is also engaged in the development and
manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs
for emerging markets catering to more than 40 countries. The company has currently approval from
regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets
with over 260 product registrations and 530 product applications. Senores also manufactures critical care
injectables and Active Pharmaceutical Ingredients (“API”).
Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved
and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in
Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also
has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and
the other in Naroda. Read also: Wockhardt Bio incorporates new wholly owned subsidiary in Ireland